Human cancers are characterized by acquired genetic alterations that are often first detected as nonrandom cytogenetic abnormalities seen in primary human tumor cultures. These changes can be further delineated at the molecular level by assessment of tumor samples for loss of heterozygosity (LOH). Human chromosome 3p14 is a common region where such alterations take place in a wide array of common neoplasia (1) (2) (3) . In addition, experiments designed to introduce a normal chromosome 3 in tumor cells have consistently demonstrated reduction in tumorigenicity following chromosome transfer (4, 5) . This locus coincides with the FRA3B site that represents a ''fragile'' site on chromosome 3p defined by the presence of characteristic chromosomal gaps following incubation of blood lymphocytes with aphidicolin (6) . Since these sites are present in unaffected subjects, the clinical implications of these alterations remain controversial (7) . Cloning of the t(3:8) (p14.2;q24) translocation breakpoint from a family with hereditary renal cell carcinoma resulted in the identification of the fragile histidine triad (FHIT) gene that has undergone an intragenic disruption in intron 3 (8) . The genomic structure of FHIT overlaps with the FRA3B fragile site and coincides with the common region of allelic loss in sporadic human cancers. Such evidence suggests the possibility that FHIT encodes for a new tumor suppressor gene.
The primary sequence of FHIT showed the strongest homology with the Schizosaccharomyces pombe asymmetrical hydrolase gene, aph1, and biochemical analysis has confirmed that the FHIT gene product is an enzyme with hydrolase activity in vitro (8, 9) . In addition, resolution of the crystal structure of a related histidine triad (HIT) protein, designated HINT, has demonstrated that the HIT motif participates in phosphate binding (10) . However, these observations have offered few clues that would allow researchers to define a role for this enzymatic activity in human tumorigenesis. While point mutations within the FHIT gene have been reported rarely, analyses of primary tumors and their derived cell lines have revealed genomic alterations detectable by Southern blot analysis as well as expression of truncated FHIT messenger RNA (mRNA) species (11, 12) . These aberrant forms include molecules containing deletions of exons 5 and 8 that are often coexpressed with a full-length mRNA species. However, variable splicing of FHIT transcripts has been noted in non-neoplastic cells, which suggests that the truncated mRNA species may not be cancer specific (13, 14) . If the FHIT gene is the target for the frequent LOH observed in human cancers, it would be predicted to exhibit tumor suppressor properties similar to those of the RB or p53 tumor suppressor genes, including the ability to inhibit cell growth in vitro and to suppress tumorigenicity in vivo.
In this study, we examined the patterns of protein expression in cells derived from human cancers and analyzed the biologic effects of ectopic FHIT expression in human carcinoma cell lines with absent endogenous FHIT protein (designated pFHIT).
Materials and Methods
FHIT complementary DNA (cDNA), amplified by polymerase chain reaction (PCR) methodology, was cloned into a pGEX bacterial expression vector (Pharmacia LKB Biotechnology AB, Uppsala, Sweden) for production of a recombinant glutathione S-transferase (GST)-pFHIT fusion protein. For expression in eukaryotic cells, the FHIT cDNA was cloned in-frame into a hemagglutinin (HA)-tag modified pcDNA3 (Invitrogen, Carlsbad, CA) plasmid, resulting in pcDNA3-HA-FHIT, and into the PCI-neo mammalian expression vector without an HA tag (Promega Corp., Madison, WI). A mutant FHIT cDNA was generated by PCR amplification with the use of overlapping sets of oligonucleotides that exclude the exon 8 sequence and was cloned into the PCI-neo vector. All FHIT expression constructs were confirmed by nucleotide sequencing with the use of dideoxy chain termination methodology (15) .
HeLa cervical carcinoma and SaOS osteosarcoma cells were obtained from the American Type Culture Collection (Rockville, MD) and propagated in Dulbecco's modified Eagle medium and 10% fetal calf serum. Cell lines H23, H125, H358, H1373, and H2122 were isolated from human lung cancer samples, as described previously (16) , and propagated in RPMI-1640 medium and 10% fetal calf serum. Transfection of the lung carcinoma and SaOS cells was performed by use of a liposome-mediated method as described by the manufacturer (Lipofectin reagent; Life Technologies, Inc. [GIBCO BRL], Gaithersburg, MD). Seventytwo hours after transfection, the culture plates were trypsinized, and the cells were transferred into 5 × 100-mm 2 plates and then exposed to RPMI-1640 medium supplemented with 10% fetal calf serum and 150 g/mL of G418 (Life Technologies, Inc.). All media used in these experiments were supplemented with 100 U/mL penicillin and 100 g/mL streptomycin. After a 2-to 3-week incubation in medium containing G418, the plates were washed in phosphatebuffered saline (PBS), fixed in 10% methanol and 10% acetic acid, and stained in 20% ethanol and 0.4% (wt/vol) crystal violet. The plates were then rinsed in water, and colonies were counted by visual inspection. RNA and protein samples were prepared from single 100-mm 2 plates. For HeLa cells, stable transfectants were subcloned after selection in G418 (800 g/mL) for 3 weeks. Colony formation assays and proliferation assays were performed as described previously (17) . Flow cytometric analyses were performed by standard techniques on stable HeLa subclones that had been transfected with pcDNA3 vector alone or with pcDNA3-HA-FHIT.
All animal studies were conducted under an institutionally approved animal care protocol. To test in vivo tumorigenicity, we gave 6-week-old immunodeficient CB17SCID mice a subcutaneous injection of approximately 3 × 10 6 cells from the HeLa parent cell line or from HeLa lines stably transfected with pcDNA3 or pcDNA3-HA-FHIT (n ‫ס‬ 4/group). Viability of these cells was assessed by the trypan blue dye exclusion test at the time of injection. Tumor size was measured bidimensionally (recorded in mm 2 ) after 3 weeks, and tumor samples were excised for protein and histologic analyses.
Two independent polyclonal antisera to pFHIT (anti-Fhit1 and anti-Fhit2) were generated by use of a GST-pFHIT fusion protein made from the full-length human FHIT cDNA. In both cases, pFHIT was confirmed to be in-frame by dideoxy sequencing (U.S. Biochemical, Cleveland, OH) and by production of an appropriate-sized GST-pFHIT fusion protein. New Zealand white rabbits received an injection of antigen three times during a 6-week period and were bled 2 weeks after the third (and any subsequent) injection. Both antibodies detected a cytoplasmic 17-kd species from human protein samples. For anti-Fhit1, the antiserum was affinity purified with the use of an Affi-Gel 10 column (Bio-Rad Laboratories, Richmond, CA) bound to thrombin-cleaved GST-pFHIT. For immunoblot analysis, cells were washed in PBS and lysed in either 10 mM TrisHCl (pH 7.4), 150 mM NaCl, 1% Nonidet P40, 1 mM EDTA, 1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 10 g/mL aprotinin, 5 g/mL leupeptin, or ELB buffer (i.e., 250 mM sodium chloride, 0.1% Nonidet P40, 50 mM HEPES [pH 7.0], 5 mM EDTA, 1 mM PMSF, and 1 g/mL leupeptin). Cell lysates were clarified by centrifugation at 12 000g for 5 minutes at 4°C, and protein concentrations were quantitated by the Bradford assay. Protein (100 g) was fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (15% gel) and blotted onto nitrocellulose membrane. After blocking with 5% nonfat dried milk-0.1% Tween 20 in PBS, the blots were incubated with either crude antisera (1 : 2000) or affinity-purified anti-pFHIT antibodies (1 : 1000). Signals were detected by use of the ECL system, according to the manufacturer's protocol (Amersham Life Science Inc., Arlington Heights, IL). For sequential immunoprecipitation-immunoblotting analysis, the cell lysates were incubated at 4°C with anti-Fhit2. After 1 hour, 50 L of washed protein A-Sepharose beads (Pharmacia LKB Biotechnology AB) was added, the mixture was incubated with rocking at 4°C for 1 hour, and the washed pellets were subjected to SDS-PAGE (15% gel). The gel was transferred to nitrocellulose, and the filter was incubated overnight at 4°C with a 1 : 100 dilution of antibody in PBS containing 5% milk and 1% bovine serum albumin. Signals were detected by use of the ECL system as directed by the manufacturer (Amersham Life Science Inc.).
Crude nuclear and cytoplasmic fractions were prepared from HL60 promyelocytic leukemia cells. A sample of 4 × 10 7 cells was washed twice in hypotonic TKM (i.e., 10 mM Tris-HCl [pH 7.4], 10 mM KCl, and 1.5 mM MgCl 2 ) and allowed to swell in TKM for 5 minutes on ice. The cells were lysed with 50 strokes of a Dounce homogenizer and centrifuged at 1000g for 5 minutes at 4°C, and the supernatant was reserved as the cytoplasmic preparation. The nuclear pellet was washed twice in cold PBS, and lysates were prepared by addition of 500 L of ELB buffer and then clarification of the lysate. The cytoplasmic preparation was made isotonic to ELB by the addition of sodium chloride, Nonidet P40, HEPES, EDTA, PMSF, and leupeptin. These preparations were used for immunoprecipitation and immunoblotting studies.
Portions of tumors excised from the CB17SCID mice were fixed in 10% formalin and embedded in paraffin. Sections (5 m thick) were stained with hematoxylin-eosin by standard procedures. Immunohistochemical analysis with affinity-purified anti-Fhit1 antiserum (1 : 20, incubated for 2 hours at room temperature) was performed with antigen retrieval by boiling in 6 M urea solution in a microwave oven. Endogenous peroxidase was blocked by use of 3% H 2 O 2 in PBS. Negative controls were incubated with PBS. The slides were washed and exposed to secondary biotinylated goat anti-rabbit antibody, and signals were detected by use of dimethylaminoazobenzene as a chromogen substrate, according to the manufacturer's protocol (ABC Elite Kit; Vector Laboratories, Inc., 
For cellular localization, blocks of pFHIT-positive and pFHIT-negative cell lines (N417 small-cell lung carcinoma and SaOS osteosarcoma, respectively) were embedded in paraffin and sectioned. Immunohistochemical staining was performed by use of either anti-Fhit2 antiserum (1 : 1000, 2 hours at room temperature), preimmune sera, or anti-Fhit2 antiserum that had been preincubated with the specific immunogen in the absence of antigen retrieval.
The unpaired Student's t test was used to compare the means of the number of independent drug-resistant colonies following transfection with the FHITexpression construct or vector alone. The means of the products of the bidimensional size of subcutaneous tumors were compared among the three groups by use of one-way analysis of variance (ANOVA). The data were analyzed by use of both the nonparametric Kruskal-Wallis test and ANOVA on log-transformed data. All P values are two-sided.
Results
We examined the expression of the FHIT gene product in 52 carcinoma cells derived from colon carcinomas, osteosarcomas, hematopoetic cancers, and lung cancers. These cell types were studied because they exhibit frequent cytogenetic and LOH abnormalities near the FRA3B/FHIT locus at chromosomal band 3p14. Immunoblot analysis, by use of polyclonal anti-pFHIT antisera, detected a specific 17-kd species corresponding to pFHIT (Fig. 1, A) . We observed that the pFHIT protein was absent in HeLa cells, in 15 of 28 small-cell lung carcinomas, in eight of 11 non-small-cell lung carcinomas, in two of three mesotheliomas, in one of three pulmonary carcinoid tumors, in one of three colon carcinomas, in two of two osteosarcomas, and in zero of one hematopoietic cell line samples (Table 1) . We simultaneously studied FHIT mRNA expression by use of a reverse transcription-PCR assay in 36 of the 52 samples on which we had pFHIT protein expression data. We observed the absence of FHIT mRNA expression in five of 36 samples, a truncated FHIT species coexpressed with a full-length FHIT transcript in six of 36 samples, and exclusive expression of full-length FHIT in 25 of 36 samples. Of the 31 samples expressing FHIT mRNA, 19 showed concordant expression of both mRNA and its protein.
In addition, in every sample in which mRNA expression was absent, there was a corresponding lack of protein expression. In contrast, pFHIT protein expression was also absent in 12 cases that expressed the full-length mRNA (10 with exclusive expression of full-length FHIT mRNA and two with coexpression of a truncated mRNA species).
To determine the subcellular localization of pFHIT, we performed biochemical fractionation to obtain cytoplasmic and crude nuclear protein fractions from HL60 cells. Sequential immunoprecipitation-immunoblotting analysis demonstrated that pFHIT was localized predominantly in the cytoplasmic compartment (Fig. 1, B) . In addition, we demonstrated the specificity of the polyclonal antisera by incubating it with excess recombinant pFHIT protein ( Fig. 1, B; lane 2) . The cytoplasmic localization was confirmed by immunohistochemical analysis of N417 small-cell lung cancer cells expressing endogenous pFHIT by use of preimmune antisera and pFHIT-specific antisera, with and without the blocking polypeptide (Fig. 2) .
To test the hypothesis that FHIT functions as a tumor suppressor gene by inhibiting cell proliferation and tumorigenicity, we undertook a series of biologic experiments to determine the effects of ectopic pFHIT expression in tumor cells that lack endogenous pFHIT. The full-length FHIT gene, with or without the HA tag, was transfected into HeLa and H23 cells, respectively. Despite high levels of transgene expression (Fig. 3, A and  B) , no difference in the number of G418-resistant colonies was detected when compared with antisense and vector controls. In contrast, transfection of the cyclin-dependent kinase inhibitor p16 ink4a showed a fivefold suppression in colony number (Fig.  4) . To exclude the possibility that the exogenous FHIT gene had undergone mutational inactivation after stable integration into transfected cells, we subcloned the exogenous FHIT minigene and subjected it to nucleotide sequencing. We confirmed that the open reading frame contained a wild-type sequence (data not shown), consistent with the observation that the transfected pFHIT protein comigrated with wild-type pFHIT. For HeLa cells, the number (mean ± standard deviation) of drug-resistant colonies was also unaltered by the expression of FHIT as compared with the vector control (29 ± 6 versus 26 ± 13; unpaired t test, P ‫ס‬ .69). In the case of the HeLa cells, the morphology of the stably FHIT-transfected cells was unchanged from the vector-alone control and the untransfected parental cells (Fig. 5,  A) . In addition, the proliferative rate was not significantly different between the pFHIT-expressing and the pFHITnonexpressing HeLa cells (Fig. 5, B) . We also introduced an exogenous FHIT gene into the pFHIT-nonexpressing tumor cell lines SaOS, H125, H358, and H1373, as well as into the pFHITexpressing tumor cell line H2122; again, we did not observe evidence of colony suppression following exogenous pFHIT expression (data not shown). Consistent with these observations, cell cycle parameters (as determined by flow cytometry) were unaffected by the high levels of pFHIT (Fig. 5, C) .
Tumorigenicity of the transfected HeLa cells was tested in 6-week-old immunodeficient B17SCID mice by subcutaneous injection of approximately 3 × 10 6 cells into the flanks of each animal. All animals harbored macroscopic disease at the site of injection within 3 weeks. There was no statistically significant difference in the bidimensional size of the tumors among the different groups (Fig. 6, A) . While there was a trend toward smaller lesions in the FHIT-transfected (1.62 ± 1.37 cm 2 [mean ± standard deviation]) versus the vector-transfected (2.32 ± 1.04 cm 2 ) group, the results of the former experiment were similar to those seen for the growth of the parental HeLa cells (1.51 ± 0.63 cm 2 ; Kruskal-Wallis, P ‫ס‬ .4; analysis of variance on logtransformed data, P ‫ס‬ .4). To rule out the possibility of rever- tant clones, we analyzed tumor lysates for pFHIT protein expression by immunoblotting analysis. Xenograft tumor samples excised from all of the mice showed the continued expression of the 17-kd pFHIT product (Fig. 6, B) . The histology of the excised xenografts from the three experimental transfectant groups was indistinguishable, exhibiting features of poorly differentiated carcinoma with occasional squamous differentiation. Consistent with the immunoblot analysis, immunohistochemical analysis of the tumors revealed high levels of pFHIT expression only in those transfected with the pcDNA3-HA-FHIT (HeLa/ FHIT) (Fig. 6, C) .
Discussion
Molecular genetic analyses of human tumors have suggested that FHIT may play a role in the development of cancers as a tumor suppressor gene. Alterations of the gene's mRNA transcripts and in its level of expression as detected by reverse transcription-PCR analysis have been reported in lung cancers, Merkel cell carcinomas, digestive tract cancers, breast cancers, head and neck squamous cell cancers, and cervical cancers (8, 12, (18) (19) (20) (21) (22) (23) . In addition, recent investigations of the bronchial epithelium of current and former smokers (24, 25) have associated both the development of LOH at chromosome 3p14 and FHIT abnormalities with smoking. However, several other studies (26) (27) (28) have failed to detect FHIT mRNA abnormalities in human colon, esophageal, or small-cell lung xenograft tumors or cell lines. Functional studies are therefore needed to examine the biologic activity of the FHIT gene product as a potential tumor suppressor.
Using specific antibodies to pFHIT, we demonstrated that 30 of 52 tumor cell lines tested have undetectable endogenous pFHIT protein by immunoblot and indirect immunohistochemical analyses. These data resemble those from recent studies (11, 29) that showed the loss of FHIT expression in a small series of gastrointestinal, genitourinary, and gynecologic tumors. We examined the biologic behavior of seven cell lines derived from different human carcinomas. Our results indicate that overexpression of pFHIT had no effect on cell morphology, cellular proliferation, or colony formation in the pFHIT-nonexpressing H23, H125, H358, H1373, SaOS, and HeLa cells or in the pFHIT-expressing H2122 cells in vitro. This finding is further substantiated by the lack of alteration in cell cycle kinetics and the lack of suppression in tumor formation in vivo in HeLa cells. It appears, therefore, that the effect of FHIT loss or inactivation during tumorigenesis is distinct from that of the ''classic'' tumor suppressor genes such as the p16/RB or p53 pathways. While this manuscript was under review, however, another study (30) was published that examined the biologic effect of FHIT replacement in a series of human cancer cell lines. While those investigators also observed no consistent effect of exogenous FHIT expression on the growth of transfected cancer cells, they detected a reduction in either the size or number of xenograft tumors in a nude mouse tumorigenicity model. Surprisingly, however, they did not detect a difference in suppression of tumorigenicity between the wild-type or mutant (with absent hydrolase enzymatic activity) FHIT genes. These data, therefore, suggest the possibility that FHIT may exert growth or tumor suppressor activity in a highly cell lineage-specific manner or that altered FHIT may be indirectly linked to tumor invasion or progression. Further work, however, is required to directly test these alternate biologic pathways. In addition, these data also suggest the possibility that other candidate tumor suppressor genes may exist in the 3p14 region. 
